Reports Q3 revenue $12.82B, consensus $12.76B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another quarter of strong operational performance in Q3, with sales up 10% and core operating income up 20%. All key growth drivers contributed to the momentum. We achieved important indications expansions for Kisqali in early breast cancer and Fabhalta in IgA nephropathy, and we completed our PSMAfore filing for Pluvicto in the US. With the momentum in our business and pipeline, we were able to once again upgrade our full-year guidance and remain highly confident in our mid-term outlook.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis Reports Strong Q3 Growth and Raises Guidance
- Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler
- Monte Rosa announces global license agreement with Novartis
- Novartis presents 12-month data from the Phase III APPEAR-C3G study
- NVS Earnings this Week: How Will it Perform?